Exact(3)
Several studies [ 15- 19, 41] were similar to our data that ICS regimen was the independent risk factor for an excess risk of pneumonia.
The use of LABA or LAMA alone may result in higher COPD-related management costs compared to managing stable patients with a LABA and LAMA regimen or a LABA, LAMA and ICS regimen.
This study also indicates that a stable COPD population managed with LABA, LAMA and ICS regimen including inhaled corticosteroids may have higher treatment costs without an offset in their other COPD-related costs compared to a matched cohort managed with a LABA and LAMA regimen.
Similar(56)
Adding a taxane to PF in the IC regimen confers a better outcome.
Induction chemotherapy (IC) regimen consisted of two drugs: Gemcitabine and Cisplatin.
A 2-year DSS and OS were significantly better with a nab-paclitaxel-based IC regimen (APF-C) compared to a docetaxel-based IC regimen (TPF-C) in p16-positive OPSCC.
In conclusion, 2-year DSS and OS were significantly better with a nab-paclitaxel-based IC regimen (APF-C) compared to a docetaxel-based IC regimen (TPF-C) in p16-positive OPSCC.
Therefore, APF-C may be an excellent IC regimen to employ for risk stratification in p16-positive OPSCC.
We hypothesized that a nab-paclitaxel-based compared to a docetaxel-based IC regimen would be better in terms of survival endpoints.
The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate.
Although a pharmacoeconomic evaluation of the two regimens was not performed, it is obvious that these two main toxicities of the IC regimen required patient hospitalisation, which is not without economic consequences.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com